A recently published study sheds light on the dramatic increase in the use of glucagon-like peptide-1 receptor agonists (GLP-1RAs) in the United States between 2017 and 2022, with semaglutide emerging as the clear leader in this therapeutic class. The investigation, which analyzed comprehensive federal survey data, points to a notable expansion in GLP-1RA prescriptions for individuals both with and without a diagnosis of diabetes. This growth is predominantly attributed to the increased adoption of semaglutide, particularly following its approval for weight management applications. Intriguingly, the study uncovers a dual trend: a reduction in patients' direct out-of-pocket expenses juxtaposed with a significant escalation in overall annual payments from all sources. This financial dichotomy brings forth critical discussions regarding the long-term economic accessibility of these medications, especially considering the potential for prolonged, even lifelong, treatment.
The growing availability and proven efficacy of GLP-1RAs, particularly in managing blood glucose levels and facilitating weight reduction, are reshaping contemporary medical practices. Initially designed for managing type 2 diabetes, these compounds have demonstrated remarkable benefits in weight loss for individuals without diabetes. Semaglutide, among these, has garnered considerable public attention due to its superior effectiveness in weight management compared to its predecessors. Despite the rapid integration of these treatments, a comprehensive understanding of their usage patterns—specifically how adoption varies across different GLP-1RA types and diabetes statuses—and the associated financial implications remained largely underexplored using nationally representative US data until now. The absence of such insights created a gap in understanding the evolving landscape of these medications, particularly concerning shifts between older and newer GLP-1RA formulations and changes in prescription expenditures over time. Monitoring these trends is crucial because GLP-1RA therapies often require extended, potentially lifelong, administration, making their affordability a paramount concern.
To bridge this knowledge gap, the current research meticulously analyzed data from the Medical Expenditure Panel Survey (MEPS), focusing on the period from 2017 to 2022. This timeframe was chosen to capture the usage and payment dynamics immediately preceding and following the expanded indications for GLP-1RAs. The study encompassed 1,878 participants, representing an estimated 20,343,000 US adults who reported GLP-1RA use during the six-year survey period. The participant pool indicated that 52% were women, and 90% had a history of diabetes, with average ages of 59.8 years for diabetic individuals and 47.8 years for non-diabetic individuals. For drug-specific analyses, semaglutide and liraglutide were examined individually, while dulaglutide, exenatide, and other unspecified GLP-1 agonists were consolidated into a single category. The primary financial metrics evaluated were mean annual out-of-pocket payments, covering patient and family contributions including deductibles, copays, and coinsurance, and mean total annual payments per person, which aggregated contributions from various sources such as Medicare, Medicaid, private insurance, and government programs. These financial endpoints were assessed over the multi-year study period to illustrate changes in per-person payments based on diabetes status and GLP-1RA type.
The analysis revealed a substantial nationwide surge in GLP-1RA usage. Among individuals with diabetes, utilization escalated by an impressive 230% from 2017 to 2022, increasing from 1,545,000 to 5,092,000 users. For those without a reported history of diabetes, the increase was even more dramatic, reaching 643%, with users growing from 115,000 to 855,000. These increases were statistically significant, with a P-value for trend of less than 0.01. Further examination pinpointed semaglutide as the primary catalyst behind this overall expansion. In 2018, semaglutide constituted only 10% of GLP-1RA users with diabetes and 8% of users without diabetes. However, by 2022, these figures had soared to 54% and 65%, respectively. Conversely, liraglutide's market share declined, dropping from 42% to 12% among diabetic users and from 58% to 21% among non-diabetic users, despite an absolute increase in its non-diabetic user base. The financial assessment presented contrasting patterns. Mean annual out-of-pocket payments for patients with diabetes decreased from $414 to $252, and for those without diabetes, from $212 to $157. In stark contrast, the mean total annual payments per user demonstrated an increase. Payments from all funding sources rose from $4,936 to $6,722 for diabetic users and from $2,651 to $6,811 for non-diabetic users. In 2022, non-diabetic individuals using semaglutide incurred a mean annual total payment of $7,588, with an average out-of-pocket expense of $162.
The study’s insights reveal that semaglutide had become the dominant GLP-1RA in the US by 2022, likely attributable to its recognized efficacy in weight management and its formal approval for this indication in 2021. While individual patient out-of-pocket expenses showed a downward trend, the elevated total annual payments are a cause for concern regarding accessibility, especially given that these treatments may be necessary for an entire lifetime. Future investigations are essential to formulate and assess policies aimed at mitigating both the overall and direct patient costs associated with GLP-1RA therapies.